Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 14c-labeled Carvedilol
2. Bm 14190
3. Bm-14190
4. Bm14190
5. Carvedilol Hydrochloride
6. Carvedilol, (+)
7. Carvedilol, (+)-isomer
8. Carvedilol, (+-)-isomer
9. Carvedilol, (-)
10. Carvedilol, (-)-isomer
11. Carvedilol, (r)-isomer
12. Carvedilol, (s)-isomer
13. Carvedilol, 14c Labeled
14. Carvedilol, 14c-labeled
15. Coreg
16. Coropres
17. Dilatrend
18. Eucardic
19. Kredex
20. Querto
1. 72956-09-3
2. Coreg
3. Dilatrend
4. Eucardic
5. Kredex
6. Carvedilolum [latin]
7. Carvedilolum
8. Querto
9. Bm 14190
10. 1-(9h-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
11. Bm-14190
12. Dimitone
13. Artist
14. Skf 105517
15. 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
16. 1-((9h-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol
17. Coronis
18. Korvasan
19. Talliton
20. Dq 2466
21. Dq-2466
22. C07ag02
23. (+-)-1-(carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
24. Chembl723
25. Nsc-758694
26. Sk&f-105517
27. Bm 14.190
28. Bm-14-190
29. Bm-14.190
30. Chebi:3441
31. 0k47ul67f2
32. [3-(9h-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine
33. 1-(9h-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
34. Skf-105517
35. (r)-bm 14190
36. (s)-bm 14190
37. Coropress
38. Dibloc
39. R-(+)-carvedilol
40. S-(-)-carvedilol
41. 1-(9h-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
42. Smr000449280
43. Artist (tn)
44. Coreg (tn)
45. Hsdb 7044
46. Sr-01000759289
47. Unii-0k47ul67f2
48. Mfcd00869663
49. 1-(9h-carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol
50. Carvedilol D5
51. Eg-p042
52. Mfcd00864692
53. Carvedilol - Bio-x
54. Bm14190
55. Carvedilol [usan:usp:inn:ban:jan]
56. Spectrum_001665
57. Carvedilol [mi]
58. Carvedilol [inn]
59. Carvedilol [jan]
60. Spectrum2_001673
61. Spectrum3_001182
62. Spectrum4_000636
63. Spectrum5_001436
64. Carvedilol [hsdb]
65. Carvedilol [usan]
66. Carvedilol [vandf]
67. Carvedilol [mart.]
68. Carvedilol [usp-rs]
69. Carvedilol [who-dd]
70. Schembl22293
71. Gtpl551
72. Kbiogr_001252
73. Kbioss_002145
74. Mls000758299
75. Mls000759508
76. Mls001424092
77. Mls006011886
78. Spbio_001885
79. Carvedilol (jp17/usp/inn)
80. Carvedilol [orange Book]
81. Dtxsid8022747
82. Schembl10082334
83. Schembl13287211
84. Bdbm25759
85. Kbio2_002145
86. Kbio2_004713
87. Kbio2_007281
88. Kbio3_002323
89. Carvedilol [ep Monograph]
90. (r)-1-[(4-carbazolyl)oxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
91. Carvedilol [usp Monograph]
92. Hms2051n03
93. Hms2089b09
94. Hms2093e12
95. Hms3261e15
96. Hms3269n11
97. Hms3393n03
98. Hms3413b14
99. Hms3655o14
100. Hms3677b14
101. Hms3715d15
102. Hms3750i15
103. Hms3884e12
104. Pharmakon1600-01504257
105. Carvedilol 1.0 Mg/ml In Methanol
106. ((c)i)-carvedilol-d4(ethyl-d4)
107. Amy40801
108. Bcp23386
109. Ex-a5746
110. Hy-b0006
111. Tox21_500347
112. Bbl029064
113. Mfcd00869664
114. Nsc758694
115. S1831
116. Stk621453
117. Akos005554967
118. Carvedilol, >=98% (hplc), Solid
119. Ac-1641
120. Bcp9000493
121. Ccg-100917
122. Ccg-207952
123. Cs-1194
124. Db01136
125. Ks-1037
126. Lp00347
127. Nc00167
128. Nsc 758694
129. Sb17441
130. Sdccgsbi-0206771.p002
131. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-
132. Ncgc00167832-01
133. Ncgc00167832-02
134. Ncgc00167832-03
135. Ncgc00167832-04
136. Ncgc00167832-19
137. Ncgc00261032-01
138. Bc164291
139. Sy129821
140. Sy283162
141. Bcp0726000253
142. Sbi-0206771.p001
143. Db-055704
144. Db-057556
145. Db-057557
146. Ft-0603055
147. Ft-0603057
148. Ft-0652640
149. Ft-0664397
150. Sw197547-3
151. C06875
152. D00255
153. F19969
154. Ab00639903-07
155. Ab00639903-09
156. Ab00639903_10
157. Ab00639903_11
158. Ab00639903_12
159. 956c093
160. L001243
161. Q412534
162. Q-200801
163. Sr-01000759289-5
164. Sr-01000759289-6
165. Sr-01000759289-9
166. Brd-a10977446-001-04-8
167. Brd-a10977446-001-05-5
168. Brd-a10977446-045-01-1
169. Z2786051695
170. Carvedilol, European Pharmacopoeia (ep) Reference Standard
171. Ethyl 2-(9-(pyridin-4-ylmethyl)-9h-fluoren-9-yl)acetate
172. Carvedilol, United States Pharmacopeia (usp) Reference Standard
173. 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol
174. Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
175. (+/-)-1-carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
176. 1-(carbazol-4-yloxy)-3-((2-(o-methoxy-phenoxy)ethyl)amino)-2-propanol
177. Carvedilol For System Suitability, European Pharmacopoeia (ep) Reference Standard
178. 107741-96-8
179. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+/-)-
Molecular Weight | 406.5 g/mol |
---|---|
Molecular Formula | C24H26N2O4 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 10 |
Exact Mass | 406.18925731 g/mol |
Monoisotopic Mass | 406.18925731 g/mol |
Topological Polar Surface Area | 75.7 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 508 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Carvedilol |
PubMed Health | Carvedilol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Drug Label | Carvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:Carvedilol tablets, US... |
Active Ingredient | Carvedilol |
Dosage Form | Tablet |
Route | Oral |
Strength | 6.25mg; 25mg; 3.125mg; 12.5mg |
Market Status | Prescription |
Company | Ranbaxy; Glenmark Generics; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Beximco Usa; Pliva Hrvatska Doo; Taro; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Cipla; Mylan; Hikma |
2 of 6 | |
---|---|
Drug Name | Coreg |
PubMed Health | Carvedilol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Drug Label | Carvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:COREG is a white, oval... |
Active Ingredient | Carvedilol |
Dosage Form | Tablet |
Route | Oral |
Strength | 6.25mg; 25mg; 3.125mg; 12.5mg |
Market Status | Prescription |
Company | Smithkline Beecham |
3 of 6 | |
---|---|
Drug Name | Coreg cr |
PubMed Health | Carvedilol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Active Ingredient | Carvedilol phosphate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 10mg; 80mg; 40mg; 20mg |
Market Status | Prescription |
Company | Sb Pharmco |
4 of 6 | |
---|---|
Drug Name | Carvedilol |
PubMed Health | Carvedilol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Drug Label | Carvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:Carvedilol tablets, US... |
Active Ingredient | Carvedilol |
Dosage Form | Tablet |
Route | Oral |
Strength | 6.25mg; 25mg; 3.125mg; 12.5mg |
Market Status | Prescription |
Company | Ranbaxy; Glenmark Generics; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Beximco Usa; Pliva Hrvatska Doo; Taro; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Cipla; Mylan; Hikma |
5 of 6 | |
---|---|
Drug Name | Coreg |
PubMed Health | Carvedilol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Drug Label | Carvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:COREG is a white, oval... |
Active Ingredient | Carvedilol |
Dosage Form | Tablet |
Route | Oral |
Strength | 6.25mg; 25mg; 3.125mg; 12.5mg |
Market Status | Prescription |
Company | Smithkline Beecham |
6 of 6 | |
---|---|
Drug Name | Coreg cr |
PubMed Health | Carvedilol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Active Ingredient | Carvedilol phosphate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 10mg; 80mg; 40mg; 20mg |
Market Status | Prescription |
Company | Sb Pharmco |
Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Vasodilator Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)
Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654
Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of greater than 40 percent (with or without symptomatic heart failure). /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654
Carvedilol is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654
For more Therapeutic Uses (Complete) data for CARVEDILOL (10 total), please visit the HSDB record page.
Carvedilol is contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol; second- or third-degree AV block; sick sinus syndrome; severe bradycardia (unless a permanent pacemaker is in place); Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol; patients with severe hepatic impairment; patients with a history of a serious hypersensitivity reaction (eg, Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol.
US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654
Patients with coronary artery disease, who are being treated with carvedilol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in angina patients following the abrupt discontinuation of therapy with beta-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of carvedilol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. Carvedilol should be discontinued over 1 to 2 weeks whenever possible. If the angina worsens or acute coronary insufficiency develops, it is recommended that carvedilol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue therapy with carvedilol abruptly even in patients treated only for hypertension or heart failure.
US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654
Worsening heart failure or fluid retention may occur during up-titration of carvedilol. If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes. Occasionally it is necessary to lower the carvedilol dose or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of, or a favorable response to, carvedilol. In a placebo-controlled trial of patients with severe heart failure, worsening heart failure during the first 3 months was reported to a similar degree with carvedilol and with placebo. When treatment was maint